Vestal Point Capital LP Sells 63,751 Shares of Lexeo Therapeutics, Inc. $LXEO

Key Points

• Vestal Point Capital LP has reduced its stake in Lexeo Therapeutics by 5.3%, now holding approximately 1,136,249 shares valued at $3.94 million.
• A recent report indicates that institutional investors own 60.67% of Lexeo Therapeutics' stock, highlighting increased interest from various hedge funds in the company.
• Analysts have set varying price targets for Lexeo Therapeutics, with an average target of $15.33 and a majority rating the stock as a "Buy."

Vestal Point Capital LP lowered its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 5.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,136,249 shares of the company's stock after selling 63,751 shares during the quarter. Vestal Point Capital LP owned 3.42% of Lexeo Therapeutics worth $3,943,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in Lexeo Therapeutics by 30.1% during the fourth quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock worth $88,000 after acquiring an additional 3,093 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Lexeo Therapeutics by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock worth $73,000 after purchasing an additional 3,714 shares during the last quarter. Barclays PLC increased its position in shares of Lexeo Therapeutics by 9.9% during the 4th quarter. Barclays PLC now owns 55,161 shares of the company's stock worth $363,000 after purchasing an additional 4,951 shares in the last quarter. Woodline Partners LP lifted its holdings in Lexeo Therapeutics by 0.8% during the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company's stock valued at $5,650,000 after purchasing an additional 6,730 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in Lexeo Therapeutics by 172.8% in the fourth quarter. Deutsche Bank AG now owns 13,226 shares of the company's stock valued at $87,000 after buying an additional 8,378 shares in the last quarter. Institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Trading Up 1.0%

Shares of LXEO traded up $0.05 on Friday, reaching $5.02. 664,462 shares of the company's stock were exchanged, compared to its average volume of 302,178. The business has a 50 day moving average price of $4.53 and a two-hundred day moving average price of $3.69. Lexeo Therapeutics, Inc. has a 12 month low of $1.45 and a 12 month high of $11.72. The stock has a market capitalization of $271.08 million, a P/E ratio of -1.54 and a beta of 1.36.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.04. Equities research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on LXEO shares. HC Wainwright cut their target price on shares of Lexeo Therapeutics from $15.00 to $9.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Chardan Capital reduced their price objective on Lexeo Therapeutics from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Oppenheimer initiated coverage on Lexeo Therapeutics in a research note on Thursday, July 31st. They issued an "outperform" rating and a $20.00 target price for the company. Finally, JPMorgan Chase & Co. cut their price target on Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating for the company in a report on Friday, May 30th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $15.33.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.